You have free access to this content

Translational Mini-Review Series on Vaccines: Monitoring of human papillomavirus vaccination

  1. J. Dillner1,*,
  2. M. Arbyn2,
  3. L. Dillner1

Article first published online: 8 APR 2007

DOI: 10.1111/j.1365-2249.2007.03384.x

Issue

Clinical & Experimental Immunology

Clinical & Experimental Immunology

Volume 148, Issue 2, pages 199–207, May 2007

Additional Information

How to Cite

Dillner, J., Arbyn, M. and Dillner, L. (2007), Translational Mini-Review Series on Vaccines: Monitoring of human papillomavirus vaccination. Clinical & Experimental Immunology, 148: 199–207. doi: 10.1111/j.1365-2249.2007.03384.x

Author Information

  1. 1

    WHO Global Reference Laboratory for HPV Diagnosis and Control, Department of Clinical Microbiology, University Hospital, SE-20502 Malmö, Sweden, and

  2. 2

    Scientific Institute of Public Health, Brussels, Belgium and European Cancer Network, IARC, Lyon, France

*Joakim Dillner, Department of Clinical Microbiology, University Hospital, Entrance 78, SE-20502 Malmö, Sweden. E-mail: joakim.dillner@skane.se

Publication History

  1. Issue published online: 8 APR 2007
  2. Article first published online: 8 APR 2007
  3. Accepted for publication 26 February 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (193K)

Keywords:

  • cancer prevention;
  • surveillance;
  • virus-like particles

Summary

Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with more rare cancers, namely cancer of the vulva, vagina, penis, anus, oropharynx and larynx. Effective prophylactic vaccines have been developed. In this review, we briefly address immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost-)effective strategies for cancer control.

View Full Article (HTML) Get PDF (193K)